- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04640909
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients
Impact of Treatment With Targeted Therapies on the Generation of Effective CAR T Cells in Patients With Chronic Lymphocytic Leukemia
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a biological study aimed at analyzing the features of CAR T cells generated in CLL patients treated with ibrutinib or venetoclax.
To this purpose, blood samples will be collected from patients with CLL before starting therapy with ibrutinib or venetoclax and after 6 and 12 months of treatment.
Anti-CD19 CAR T cells will be generated and tested for: (i) viability, expansion and generation efficiency; (ii) phenotypic characteristics, in terms of CD4/CD8 composition, differentiation subset distribution, exhaustion markers and expression of immune checkpoint molecules; (iii) in vitro functional properties, in terms of proliferation ability, cytokines production, cytotoxic activity and killing of target cells. CAR T cells produced from the same patient at different timepoints will be compared. Phenotypic and functional data on CAR T cells will be also correlated with main CLL prognostic factors (e.g. IGHV mutational status, FISH abnormalities, TP53 mutation status) and outcome variables (response status, duration of response).
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Milano, Italien
- Rekruttering
- Irccs Ospedale S. Raffaele - Milano - Unità Neoplasie Linfocitarie B
-
Kontakt:
- Lydia Scarfò
- Telefonnummer: 3476866923
- E-mail: scarfo.lydia@hsr.it
-
Torino, Italien
- Rekruttering
- Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia - Università Degli Studi Di Torino
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosis of CLL/SLL meeting the IWCLL 2008 criteria;
- ≥18 years old;
- Indication for treatment with targeted therapies (i.e. ibrutinib or venetoclax);
- Anticipated possibility to collect blood samples at the baseline and at 6- and 12-month timepoints;
- Signed written informed consent according to ICH/EU/GCP and national local laws;
- Confirmed availability of the laboratory to enroll and to process patient samples.
Exclusion Criteria:
- Expected treatment duration with targeted drug < 12 months, according to treating physician;
- Previously treated with more than 2 lines of CLL-directed therapy;
- Concurrent use of systemic steroids or chronic use of immunosuppressive medications;
- Active HBV (HBsAg+ or HBV DNA+) or HCV or HIV infection.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: CAR T Cells generation
CAR T Cells generation at baseline and after 6 and 12 months of treatment
|
Peripheral blood samples evaluation
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Cell killing rate of anti-CD19 CAR T cells
Tidsramme: After 12 months of treatment
|
Assessment of the cytotoxic functions of anti-CD19 CAR T cells generated from CLL patients in terms of cell killing rate before and during treatment with targeted agents (i.e.
ibrutinib or venetoclax).
|
After 12 months of treatment
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CLL2020
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kronisk lymfatisk leukæmi
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Novartis PharmaceuticalsLedigPrimær myelofibrose (PMF) | Polycytæmi Vera (PV) | Post polycytæmi myelofibrose (PPV MF) | Trombocytæmi myelofibrose (PET-MF) | Alvorlig/meget svær COVID-19 sygdom | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)